Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital
Clinical Infectious Diseases · 20.05.2026 · 82 (5) · 808-814
DOI: 10.1093/cid/ciaf390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 16.07.2025. Verfasst von Sergio Alvarez Mulett und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health, Infectious Diseases and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Metagenomics, Central Nervous System Infections, Cerebrospinal Fluid. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
Central nervous system (CNS) infections are significant causes of morbidity and mortality, especially when diagnosis is delayed. Traditional cerebrospinal fluid diagnostic methods for CNS infections have limited sensitivity. Metagenomic next-generation sequencing of cerebrospinal fluid (MSCSF) is a newer diagnostic tool capable of detecting a broad range of pathogens in a single assay.
Methods
This retrospective cohort study evaluated the first-year experience with MSCSF at Mayo Clinic. A total of 422 tests performed during calendar year 2024 on adult patients at Mayo Clinic facilities and those tested through Mayo Clinic Laboratories were analyzed, with a subcohort analysis of the 210 Mayo Clinic patients performed to define patient characteristics associated with positive results and clinical outcomes.
Results
The sensitivity of MSCSF for detecting neuroinfection in the subcohort was 64%, with 43% of confirmed neuroinfections diagnosed by MSCSF only. Subjects who were immunosuppressed (odds ratio [OR]: 3.5, P = .008) and those with a high pretest probability of CNS infection (OR: 20.1, P < .001) were more likely to have positive results. Also, those who tested positive were more likely to die within the ensuing 30 days than those who tested negative (OR: 5.2, P = .001).
Conclusions
MSCSF can be a valuable tool for diagnosing CNS infection but should not be used indiscriminately. It appears to be most beneficial when there is a high clinical suspicion of CNS infection and conventional diagnostics, and available molecular tests, yield negative results. Its integration into clinical practice should be guided by diagnostic stewardship to maximize cost-effectiveness and clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Public Health, Infectious Diseases and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Sergio Alvarez Mulett, Sofia Molina Garcia, Omar Abu Saleh, Nancy L Wengenack, Robin Patel
Zitieren
APA
Alvarez Mulett, S., Molina Garcia, S., Abu Saleh, O., Wolf, M. J., Rodning, A. A., Wengenack, N. L., Norgan, A. P., & Patel, R. (2026). Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital. Clinical Infectious Diseases, 82(5), 808-814. https://doi.org/10.1093/cid/ciaf390
Vancouver
Alvarez Mulett S, Molina Garcia S, Abu Saleh O, Wolf MJ, Rodning AA, Wengenack NL, et al. Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital. Clinical Infectious Diseases. 2026;82(5):808-814. doi:10.1093/cid/ciaf390
BibTeX
@article{AlvarezMulett2026,
author = {Alvarez Mulett, Sergio and Molina Garcia, Sofia and Abu Saleh, Omar and Wolf, Matthew J and Rodning, Amanda A and Wengenack, Nancy L and Norgan, Andrew P and Patel, Robin},
title = {Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {5},
pages = {808--814},
doi = {10.1093/cid/ciaf390}
}
EUVIMED